Merck & Co., Inc. (mrk)
MRK — Company Overview
Merck & Co., Inc. (MRK) is a mega-cap company in the Healthcare sector, operating in Drug Manufacturers - General.
| Ticker | MRK |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NYQ |
| Market cap | $317.05B |
| Last price | $128.37 |
| Size category | Mega Cap |
MRK — Business Description
Merck & Co., Inc. (MRK) operates in Drug Manufacturers - General within the broader Healthcare market. Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax,…
Official website: https://www.merck.com.
MRK — Investment Thesis
The investment thesis for Merck & Co., Inc. (MRK) rests on how Healthcare dynamics, profitability, and valuation interact at today's price.
- Revenue is expanding at roughly 5.1% year-over-year (public data).
- Trailing P/E of 102.70× implies elevated growth expectations at the current price.
- Forward P/E (13.37×) is below trailing P/E — earnings may be expected to improve.
- Dividend yield near 2.6% adds an income component to total return.
- Equity market capitalization is approximately $317.05B.
Analyst consensus, price targets & estimates is available in Vest Terminal for Professional and Enterprise subscribers.
MRK — Financial Health
Financial health for Merck & Co., Inc. (MRK) is summarized from publicly reported profitability, leverage, and cash-flow metrics.
Profit margin near 4.8% leaves a narrower cushion versus higher-margin peers. Debt-to-equity of 106.94 warrants monitoring in a higher-rate environment.
| Trailing P/E | 102.70× |
| Forward P/E | 13.37× |
| Price / Sales | 4.76× |
| Price / Book | 6.91× |
| Gross margin | 76.0% |
| Operating margin | -1.4% |
| Profit margin | 4.8% |
| Debt / Equity | 106.94 |
MRK — Growth Outlook
Growth outlook for Merck & Co., Inc. (MRK) depends on demand trends in Drug Manufacturers - General and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 5.1% suggests steady but measured expansion.
- Price is 4.9% below the 52-week high.
MRK — Competitive Position
Merck & Co., Inc. (MRK) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Drug Manufacturers - General.
- Market capitalization of $317.05B places MRK among mega-cap peers.
- Gross margin near 76.0% may reflect pricing power or favorable mix.
MRK — Strengths
Strengths for Merck & Co., Inc. (MRK) inferred from public financial metrics:
- Revenue growth of 5.1% year-over-year.
- Gross margin of 76.0% supports competitive unit economics.
- Dividend yield of 2.6% for income-oriented holders.
- Mega Cap scale ($317.05B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
MRK — Weaknesses
Weaknesses and pressure points for Merck & Co., Inc. (MRK) based on available data:
- Elevated trailing P/E (102.70×) limits valuation margin of safety.
- Thin profit margin (4.8%).
MRK — Opportunities
- Dividend yield of 2.6% appeals to total-return investors.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
MRK — Risks
- Rich valuation (P/E 102.70×) increases downside if growth slows.
- Thin margins leave less room for operational missteps.
MRK — Summary
Merck & Co., Inc. (MRK) is a mega-cap Healthcare company focused on Drug Manufacturers - General, listed on NYQ. Last price $128.37 with market cap $317.05B. Trailing P/E 102.70×. Revenue grew 5.1% year-over-year per public data. Notable strengths include revenue growth of 5.1% year-over-year. Key watch items include elevated trailing p/e (102.70×) limits valuation margin of safety. Detailed estimates, ownership, and news for Merck & Co., Inc. remain locked in Vest Terminal for subscribers.
Merck & Co., Inc. FAQ
What does Merck & Co., Inc. (MRK) do?
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerb…
What is MRK's P/E ratio?
Merck & Co., Inc. has a trailing P/E of 102.70× based on publicly available market data.
Does MRK pay a dividend?
Indicated dividend yield: 2.6%. Confirm ex-dates and payout history in Vest Terminal.
What sector is MRK in?
Merck & Co., Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is MRK's market capitalization?
Approximate market cap: $317.05B.
What are the main risks for MRK?
Key risks include elevated valuation, among factors on this page.
What are the strengths of MRK?
Potential positives include revenue growth of 5.1% year-over-year, gross margin of 76.0% supports competitive unit economics.
Where can I get analyst estimates for MRK?
Consensus estimates, price targets, and detailed analyst data for Merck & Co., Inc. are available to Professional subscribers in Vest Terminal — not on this public summary page.